Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1916 in Locally Advanced or Metastatic Solid Tumors
NCT04842630Phase 1Terminated
- Sponsor
- Hengrui
- Start
- Apr 2021
- Primary completion
- Nov 2022
- Modality
- PEGylated Peptides, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-1916 in solid tumor, sponsored by Hengrui. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerable Dose at 21 days and 1 more. Started Apr 2021; status: terminated.
02
Drugs
SHR-1916
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04842630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842630.